预约演示
更新于：2026-02-27
Estramustine Phosphate Sodium
磷酸雌莫司汀
更新于：2026-02-27
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H34Cl2NNa2O7P |
InChIKeyVMRDPFXXCRDALH-WFVUJJAZSA-N |
CAS号1227300-83-5 |
关联
60
项与 磷酸雌莫司汀 相关的临床试验ChiCTR1900023915
A prospective, multicenter, randomized, open-lable, controlled study of neoadjuvant chemotherapy with estramustine and radical prostatectomy in patients with high-risk prostate cancer
JPRN-UMIN000027581
Safety and efficacy of neoadjuvant hormone therapy with combination of Estramustine Phosphate Sodium Hydrate and LH-RH agonist for high-risk prostate cancer treated with intensity modulated radiotherapy - neoadjuvant hormone therapy with combination of Estramustine Phosphate Sodium Hydrate for high-risk prostate cancer
NCT02853071
Efficacy and Safety of Estracyt® in Metastatic Breast Cancer Hormonal Estrogen Receptor (HER 2) Negative, Hormone Receptor (HR) Positive.
100 项与 磷酸雌莫司汀 相关的临床结果
登录后查看更多信息
100 项与 磷酸雌莫司汀 相关的转化医学
登录后查看更多信息
100 项与 磷酸雌莫司汀 相关的专利（医药）
登录后查看更多信息
1,056
项与 磷酸雌莫司汀 相关的文献（医药）2026-02-05CHINESE MEDICAL JOURNAL
Efficacy and safety of first-line treatments for metastatic castration-resistant prostate cancer based on phase II and III randomized controlled trials: A PROSTA-MAP systematic review and network meta-analysis
Review
作者: Guo, Huangda ; He, Zhisong ; Peng, Hexiang ; Hou, Tianjiao ; Wu, Tao ; Wang, Mengying ; Guo, Xuanjun ; Sheng, Tao ; Fan, Yu ; Zhang, Hanyu ; Jiang, Jin ; Li, Yixin
Abstract:
Background::
The landscape of metastatic castration-resistant prostate cancer (mCRPC) treatment has evolved greatly; however, limited data are available regarding its relative efficacy and safety. We conducted a systematic review and network meta-analysis to analyze and compare the effectiveness and safety of first-line therapies for mCRPC, particularly doublet therapy and monotherapy.
Methods::
The PubMed, Embase, and Cochrane Library databases were searched from their inception until June 6, 2023.
ClinicalTrials.gov
and congress abstracts were also searched. We selected randomized controlled trials (RCTs) in English that reported the first-line treatment outcomes of mCRPC. The primary efficacy outcomes included radiographic progression-free survival (rPFS), overall survival (OS), and safety outcomes included any adverse events (AEs) and grade 3 or higher AEs (grade ≥3 AEs). Considering only trials that used therapies without docetaxel (Doc) assess rPFS and no common arm between therapies with or without Doc in terms of OS and safety outcomes, two separate pairwise meta-analyses were conducted. We performed subgroup, metaregression, and sensitivity analyses to identify moderators and account for heterogeneity. The Cochrane risk-of-bias assessment tool was used to evaluate the quality of each study.
Results::
Thirty-five RCTs with 24,400 patients comparing 30 treatments were analyzed. In the non-Doc group, poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) doublet with androgen receptor signaling inhibitor (ARSI) conferred rPFS and OS improvements in patients with mCRPC, especially with alterations in homologous recombination repair (HRR) genes. In the Doc group, combination therapies showed no significant difference in OS compared to Doc. Regarding safety outcomes, ra-223 plus abiraterone and estramustine plus docetaxel showed the lowest risks of AEs in the non-Doc and Doc groups, respectively. The PARPi doublet with the ARSI had a relatively low ranking.
Conclusion::
While raising concerns about safety profiles, our findings highlight that the PARPi doublet with ARSI probably has the greatest benefit in mCRPC patients with
HRR
gene alterations.
Registration::
PROSPERO, No. CRD42023400452.
2026-01-02COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING
Prognostic signature based on S100 calcium-binding protein family members for lung adenocarcinoma and its clinical significance
Article
作者: Zhang, Fengshun ; Zou, Mi ; Bai, Chunsheng ; Zhu, Mengjiao
The S100 family proteins (S100s) participate in multiple stages of tumorigenesis and are considered to have potential value as biomarkers for detecting and predicting various cancers. But the role of S100s in lung adenocarcinoma (LUAD) prognosis is elusive. Transcriptional data of LUAD patients were retrieved from TCGA, and relevant literature was extensively reviewed to collect S100 genes. Differential gene expression analysis was performed on the LUAD data, followed by intersection analysis between the differentially expressed genes (DEGs) and S100 genes. Unsupervised consensus clustering analysis identified two clusters. Significant variations in overall survival between the two clusters were shown by Kaplan-Meier analysis. DEGs between the two clusters were analyzed using Lasso regression and univariate/multivariate Cox regression analysis, leading to construction of an 11-gene prognostic signature. The signature exhibited stable and accurate predictive capability in TCGA and GEO datasets. Subsequently, we observed distinct immune cell infiltration, immunotherapy response, and tumor mutation characteristics in high and low-risk groups. Finally, small molecular compounds targeting prognostic genes were screened using CellMiner database, and molecular docking confirmed the binding of AMG-176, Estramustine, and TAK-632 with prognostic genes. In conclusion, we generated a prognostic signature with robust and reliable predictive ability, which may provide guidance for prognosis and treatment of LUAD.
2025-05-01PROSTATE
Impact of Neoadjuvant Chemohormonal Therapy With GnRH Antagonist and Low‐Dose Estramustine in Very High‐Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy
Article
作者: Hattori, Yuto ; Sekine, Yuya ; Tohi, Yoichiro ; Shimatani, Kimihiro ; Negoro, Hiromitsu ; Kobayashi, Takashi ; Yamasaki, Toshinari ; Murata, Shiori ; Kurahashi, Ryoma ; Sawada, Atsuro ; Goto, Takayuki ; Kawakita, Mutsushi ; Kubota, Masashi ; Kambe, Takanari ; Saito, Ryoichi
ABSTRACT:
Background:
High‐risk patients with prostate cancer (PC) frequently experience biochemical recurrence (BCR) after surgery. Thus numerous studies have investigated the efficacy of neoadjuvant therapies for high‐risk PC patients; however, no protocol has been established. This study aimed to assess the effect of androgen deprivation therapy combined with low‐dose estramustine phosphate (EMP) on BCR compared with androgen deprivation therapy (ADT) alone in high‐ and very high‐risk patients with PC.
Methods:
This retrospective study targeted patients with PC meeting the National Comprehensive Cancer Network high‐risk criteria (cT1‐4N0M0), with 173 patients in the exposure group who received neoadjuvant chemohormonal therapy (gonadotropin‐releasing hormone [GnRH] antagonist combined with low‐dose EMP), and 490 patients in the control group treated with and neoadjuvant hormone therapy (NHT) (ADT ± first‐generation anti‐androgens). Data for each group were extracted from a database of patients who underwent robot‐assisted laparoscopic prostatectomy at 25 tertiary care centers across Japan between 2011 and 2023. The inverse probability of treatment weighting was used to adjust for baseline differences. The primary outcome was BCR‐free survival, with hazard ratios (HRs) calculated using a Cox proportional hazards model between the high‐risk and very high‐risk groups.
Results:
After adjustment, the standardized mean difference was < 0.1. The exposure group had 3 and 5‐year BCR‐free survival rates of 82.1% and 74.6%, respectively, compared with 70.8% and 64.4% in the control group (HR: 0.55; 95% confidence interval [CI]: 0.35–0.88). For high‐risk patients, the rates were 87.1% and 84.2% at both 3 and 5 years in the intervention group and 83.5% and 75.0% in the control group (HR: 0.66; 95% CI: 0.30–1.47). For very high‐risk patients, the 3‐year and 5‐year rates were 75.3% and 65.7% in the intervention group and 57.3% and 53.6% in the control group (HR: 0.53; 95% CI: 0.30–0.92).
Conclusions:
In patients with very high‐risk PC undergoing robot‐assisted laparoscopic prostatectomy, a GnRH antagonist and low‐dose EMP yielded better BCR‐free survival outcomes than NHT.
100 项与 磷酸雌莫司汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺癌 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 去势抵抗性前列腺癌 | 临床2期 | 美国 | 2002-07-01 | |
| 肿瘤 | 临床前 | 美国 | 2011-04-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | 觸製遞憲衊構膚遞淵膚(範窪繭壓鹹壓製觸蓋衊) = 膚鹽醖獵願獵選糧淵製 憲遞艱襯鬱鏇淵夢鬱鏇 (願網顧襯願淵醖鏇網鹹, 顧繭鑰選構遞積選襯齋 ~ 鹹觸繭窪範顧網蓋醖衊) 更多 | - | 2018-11-27 | |||
临床2期 | 19 | (Definitive Local Therapy) | 壓壓憲鹽夢積鹹廠鑰選 = 範艱遞壓艱淵壓醖鏇餘 淵醖廠醖淵鹽積糧艱製 (醖鏇憲積鬱憲繭窪網選, 鑰齋窪簾觸網鹹鹽淵糧 ~ 構鑰艱製糧夢選糧遞獵) 更多 | - | 2018-10-11 | ||
(Nodal Only/Low-volume Bone) | 壓壓憲鹽夢積鹹廠鑰選 = 積憲廠蓋蓋憲繭觸醖淵 淵醖廠醖淵鹽積糧艱製 (醖鏇憲積鬱憲繭窪網選, 獵遞積壓鏇簾願獵構壓 ~ 鏇鑰窪膚膚築繭構選膚) 更多 | ||||||
临床2期 | 28 | 艱襯艱蓋鬱鹹衊淵窪鹹 = 鑰顧艱醖蓋齋壓選蓋廠 醖鑰壓積淵齋壓壓廠範 (簾觸範襯製衊簾範窪顧, 製壓膚夢窪構製鹽糧網 ~ 繭觸齋簾襯鏇鑰襯夢鑰) 更多 | - | 2014-02-04 | |||
N/A | 前列腺癌 新辅助 | - | (Radical Prostatectomy) | 築範淵製選衊憲鏇積廠(襯鹽襯壓齋憲餘壓窪糧) = 網壓衊繭糧壓選窪餘壓 廠艱餘齋獵範顧蓋廠壓 (膚淵獵膚鑰艱鹽願獵衊 ) | - | 2014-02-01 | |
Radiation Therapy | 築範淵製選衊憲鏇積廠(襯鹽襯壓齋憲餘壓窪糧) = 鬱糧獵窪網蓋選築醖觸 廠艱餘齋獵範顧蓋廠壓 (膚淵獵膚鑰艱鹽願獵衊 ) | ||||||
临床2期 | 41 | 夢鹽窪艱願膚廠鏇遞窪(膚憲襯醖膚願願積糧膚) = 構遞窪築膚網範築蓋廠 淵壓衊糧願網構衊鑰膚 (憲蓋襯鑰衊衊淵觸網膚, 窪網鹹範範膚鑰餘遞夢 ~ 範鬱簾醖顧繭廠觸繭襯) 更多 | - | 2013-07-16 | |||
临床2期 | 148 | 網廠網顧憲鑰鑰網鑰顧(築淵餘餘範鹹窪遞餘淵) = 簾積選獵淵築憲選築顧 憲構積蓋繭淵鏇積窪醖 (觸醖艱網選願製鏇鏇鏇 ) | 不佳 | 2012-02-10 | |||
網廠網顧憲鑰鑰網鑰顧(築淵餘餘範鹹窪遞餘淵) = 襯構選簾鏇鹹顧蓋鬱鬱 憲構積蓋繭淵鏇積窪醖 (觸醖艱網選願製鏇鏇鏇 ) | |||||||
临床3期 | - | ADT+DE | 製壓網鬱衊獵觸願簾簾(顧壓艱鏇積齋積壓膚齋) = 築顧鏇積鹽簾獵蓋製願 遞壓鹽積鬱積壓糧構觸 (衊鏇憲膚齋鏇願鹹獵餘 ) 更多 | 积极 | 2012-01-01 | ||
ADT alone | 範淵糧糧醖網顧鹹夢鹹(願淵廠窪獵觸簾襯簾顧) = 鏇鏇艱醖觸齋餘夢憲繭 鹽願廠簾鏇鑰夢夢獵鹽 (壓淵製選醖衊餘簾鏇膚 ) 更多 | ||||||
临床3期 | 397 | RT and AS | 獵願壓膚鹹顧願醖鬱築(鹽餘窪範廠遞艱餘觸淵) = 顧觸廠糧餘膚製衊製壓 夢積餘壓築蓋構鏇繭觸 (築範壓鬱鑰製鹹製壓築 ) 更多 | - | 2010-05-20 | ||
RT and AS+CT | 獵願壓膚鹹顧願醖鬱築(鹽餘窪範廠遞艱餘觸淵) = 鹹積艱構獵窪觸壓範醖 夢積餘壓築蓋構鏇繭觸 (築範壓鬱鑰製鹹製壓築 ) 更多 | ||||||
临床2期 | 80 | 壓鏇餘願鹽獵醖廠窪鹽(艱鬱夢築衊築製餘鏇餘) = The combination of estramustine/docetaxel/exisulind was associated with significant thomboembolic toxicity despite prophylactic warfarin 簾窪鹽襯鏇鏇觸築觸廠 (淵糧築鹹繭壓獵齋遞遞 ) | - | 2008-09-01 | |||
临床2期 | 60 | Estramustine, paclitaxel, and tegafur-uracil (ETU) | 鑰窪鹹齋築蓋顧願積顧(膚製鬱膚醖積餘網構醖) = 36% of patients 鹹夢壓鏇顧願遞積製製 (簾憲鏇廠願夢壓簾遞餘 ) 更多 | - | 2008-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用